Nuvalent, Inc.
NUVL
Rankning i aktier
#2112
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Aktiekurs
$123.96
Senast synkroniserad: 2026-07-21
Marknadsvärde
$9.75B
Förändring (1 dag)
0.00%
Förändring (1 år)
27.56%
Land
US
Handel Nuvalent, Inc. (NUVL)
Kategori
Healthcare
P/B-tal för Nuvalent, Inc. (NUVL)
P/B-tal per October 2026 TTM: 8.30
Enligt Nuvalent, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 8.30. I slutet av 2023 hade företaget ett P/B-tal på 6.12.
Historik för P/B-tal för Nuvalent, Inc. från 2019 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 8.30 | 70.86% |
| 2024 | 4.86 | -20.55% |
| 2023 | 6.12 | 91.44% |
| 2022 | 3.19 | 119.56% |
| 2021 | 1.46 | -98.54% |
| 2020 | 99.44 | -289.54% |
| 2019 | -52.46 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | -24.72% |
US
|
|
| 13.2547 | 59.62% |
US
|
|
| 4.208 | -49.33% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -25.55% |
NL
|
